Clinigen Group has signed an exclusive agreement with Lukare Medical to manage the supply and distribution of Elliotts B Solution.
Under the terms of this supply and distribution agreement with Lukare, Clinigen will provide physicians and pharmacists with access to Elliotts B Solution on an unlicensed, on-demand basis for patients around the world, excluding the US and Canada.
Marketing authorization is granted in the United States, but Elliotts B Solution is currently unavailable to meet patient needs elsewhere in the world.
Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) is a diluent for methotrexate sodium, a chemotherapeutic drug and immune system suppressant, and cytarabine, a chemotherapeutic drug. These products require intrathecal administration (into the cerebrospinal fluid) for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma.
"We look forward to working with Lukare Medical to make Elliotts B Solution available on an unlicensed basis outside the US and Canada,” Julie Gosper, Head of Global Access, Clinigen, said. “This partnership demonstrates our ongoing commitment to supply the right medicine to the right patient at the right time, to improve the quality of people’s lives around the world."